Both Brand Lobbies Oppose Several Proposals In HHS Drug-Price Blueprint

The brand drug lobbies oppose several of the proposals in HHS' so-called blueprint for lowering drug prices, including proposals to change Part D coverage rules, apply Part D negotiation techniques to Part B, revive the Part B Competitive Acquisition Program, eliminate the Medicaid rebate cap and disclose list prices in drug ads. HHS Secretary Alex Azar said his top priority is moving Part B doctor-administered drugs into Part D where plans and pharmacy benefit managers negotiate prices. Both the Pharmaceutical...